- Home
- RLTY vs SOPH Comparison
RLTY vs SOPH Comparison
Compare RLTY & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLTY | SOPH |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 462.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RLTY | SOPH |
|---|---|---|
| Price | $14.61 | $8.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 43.9K | ★ 642.5K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.09 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.04 | $3.37 |
| 52 Week High | $16.41 | $8.98 |
Technical Indicators
Market Signals| Indicator | RLTY | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 26.08 | 55.33 |
| Support Level | $14.40 | $4.63 |
| Resistance Level | $15.92 | $8.98 |
| Average True Range (ATR) | 0.23 | 0.43 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 8.93 | 57.26 |
Price Performance
Historical ComparisonAbout RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.